BioSpace News Archive

Genetown

Blueprint Medicines Announces Publication in The Lancet Oncology Showing Durable Clinical Benefits of AYVAKIT™ (avapritinib) in NAVIGATOR Trial Patients with PDGFRA D842V Mutant GIST

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that The Lancet Oncology published data from the NAVIGATOR clinical trial showing an unprecedented overall survival (OS) rate and a well-tolerated safety profile for AYVAKIT™

June 29, 2020
·
7 min read
Pharm Country

MEI Recognized by MM&M as Top 100 Medical Marketing and Communications Company

MEI, a leading AI-driven medical communications and commercialization solutions provider, was recently recognized in the MM&M Top 100 report, which identifies the leading companies in medical marketing and communications.

June 29, 2020
·
1 min read
Drug Development

Health Canada Allows COVID-19 Patients with Respiratory Failure to Be Given NuvOx Pharma’s Oxygen Therapeutic in Phase IIa Clinical Trial

NuvOx Pharma, a Tucson-based biotechnology company developing NanO2™ emulsion for oxygen delivery, has received a “No Objection Letter” from Health Canada to proceed with a Phase IIa clinical trial of NanO2 in COVID-19 subjects with acute hypoxic respiratory failure (AHRF).

June 29, 2020
·
2 min read